Sage Journals: Discover world-class research

Retricted access

Other

First published 1995-4

Interim Analyses: An FDA Reviewer's Experience and Perspective *

A. J. Sankoh

Therapeutic Innovation & Regulatory Science

Retricted access

Research article

First published 2008-9

Some Guidelines for Interim Data Review of Clinical Trial Data

Dennis W. King, Jeremy D. Jokinen

Therapeutic Innovation & Regulatory Science

Retricted access

Other

First published 1999-1

Interim Analyses: An Update of an FDA Reviewer's Experience and Perspective *

A. J. Sankoh

Therapeutic Innovation & Regulatory Science

Retricted access

Research article

First published 1986-7

Interim Analyses in Randomized Clinical Trials

Stuart J. Pocock, Nancy L. Geller

Therapeutic Innovation & Regulatory Science

Retricted access

Research article

First published 2017-2

The Selection of an Interim CEO

Christine H. Mooney, Matthew Semadeni, Idalene F. Kesner

Journal of Management

Retricted access

Research article

First published 1997-4

Application of Adaptive Interim Analysis in Pharmacology

Ludwig A. Hothorn, Ullrich Martin

Therapeutic Innovation & Regulatory Science

Retricted access

Other

First published 1993-7

Discussion for Interim Analysis and Sample Size Reestimation

Karl E. Peace

Therapeutic Innovation & Regulatory Science

Retricted access

Research article

First published 2016-8

Effects of Interim Assessments Across the Achievement Distribution

Spyros Konstantopoulos, Wei Li, Shazia R. Miller [...]

Educational and Psychological Measurement

Retricted access

Research article

First published 2003-5

Ron Brown

Review & Expositor

Retricted access

Other

First published 2003-7

An Example of an Unblinded,Third-Party Interim Analysis for Sample Size Re-Estimation

Simon Kirby, Scott McBride, Lohita Puvanarajan

Therapeutic Innovation & Regulatory Science

Search results

Interim Analyses: An FDA Reviewer's Experience and Perspective *

Some Guidelines for Interim Data Review of Clinical Trial Data

Interim Analyses: An Update of an FDA Reviewer's Experience and Perspective *

Interim Analyses in Randomized Clinical Trials

The Selection of an Interim CEO

Application of Adaptive Interim Analysis in Pharmacology

Discussion for Interim Analysis and Sample Size Reestimation

Effects of Interim Assessments Across the Achievement Distribution

Interim or Intentional Interim©

An Example of an Unblinded,Third-Party Interim Analysis for Sample Size Re-Estimation